{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T23:13:47Z","timestamp":1790118827819,"version":"4.0.1"},"reference-count":38,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,3,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>BACKGROUND<\/jats:title>\n                  <jats:p>Blockade of the renin\u2013angiotensin system (RAS) represents a main strategy in the therapy of heart failure with reduced ejection fraction (HFrEF), but the role of active renin concentration (ARC) for guiding therapy in the presence of an RAS blockade remains to be established. This study assessed angiotensin profiles of HFrEF patients with distinct RAS activations as reflected by ARC.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>METHODS<\/jats:title>\n                  <jats:p>Two cohorts of stable chronic HFrEF patients on optimal medical treatment (OMT) were enrolled. We assessed ARC and all known circulating angiotensin metabolites, including AngI and AngII, by mass spectrometry to investigate the effect of different therapy modalities. Low- and high-renin HFrEF patients were identified by ARC screening and subsequently characterized by their angiotensin profiles.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>RESULTS<\/jats:title>\n                  <jats:p>Although different modes of RAS blockade resulted in typical AngII\/AngI ratios, concentrations of (AngI+AngII) strongly correlated with ARC [r = 0.95, P &amp;lt; 0.001] independent of therapy mode. Despite RAS blocker treatment with angiotensin-converting enzyme inhibitors (ACE-I) or angiotensin II type 1 receptor blockers (ARB), which anticipated ARC upregulation, about 30% of patients showed lower\/normal range ARC values. ARC did not correlate with N-terminal pro-B-type natriuretic peptide (NT-proBNP) concentrations and New York Heart Association (NYHA) stages. Angiotensin concentrations were profoundly diminished for the low-ARC group compared with the high-ARC group: AngI [6.4 ng\/L (IQR: 2.1\u201312.5) vs 537.9 ng\/L (IQR: 423.1\u2013728.4), P &amp;lt; 0.001 for ACE-I; and 4.5 ng\/L (IQR: 1.4\u201311.2) vs 203.0 ng\/L (IQR: 130.2\u2013247.9), P = 0.003 for ARB] and AngII [&amp;lt;1.4 ng\/L (IQR: &amp;lt;1.4\u20131.5) vs 6.1 ng\/L (IQR: 2.0\u201311.1), P = 0.002 for ACE-I and 4.7 ng\/L (IQR: &amp;lt;1.4\u201312.3) vs 206.4 ng\/L (IQR: 142.2\u2013234.4), P &amp;lt; 0.001 for ARB].<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>CONCLUSIONS<\/jats:title>\n                  <jats:p>In addition to NT-proBNP and NYHA stages, ARC enables classification of HFrEF patients receiving OMT into more distinguished neurohumoral HFrEF phenotypes, offering a rationale for adaptive therapeutic interventions.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1373\/clinchem.2017.278705","type":"journal-article","created":{"date-parts":[[2017,11,14]],"date-time":"2017-11-14T17:35:20Z","timestamp":1510680920000},"page":"597-608","source":"Crossref","is-referenced-by-count":61,"title":["Low- and High-renin Heart Failure Phenotypes with Clinical Implications"],"prefix":"10.1093","volume":"64","author":[{"given":"Noemi","family":"Pavo","sequence":"first","affiliation":[{"name":"Department of Internal Medicine II, Clinical Division of Cardiology, Medical University of Vienna, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georg","family":"Goliasch","sequence":"first","affiliation":[{"name":"Department of Internal Medicine II, Clinical Division of Cardiology, Medical University of Vienna, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raphael","family":"Wurm","sequence":"first","affiliation":[{"name":"Department of Internal Medicine II, Clinical Division of Cardiology, Medical University of Vienna, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Novak","sequence":"first","affiliation":[{"name":"Department of Internal Medicine II, Clinical Division of Cardiology, Medical University of Vienna, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido","family":"Strunk","sequence":"first","affiliation":[{"name":"Complexity Research, Vienna, Austria; FH Campus Vienna, Vienna, Austria, and Technical University Dortmund, Dortmund, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariann","family":"Gy\u00f6ngy\u00f6si","sequence":"first","affiliation":[{"name":"Department of Internal Medicine II, Clinical Division of Cardiology, Medical University of Vienna, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marko","family":"Poglitsch","sequence":"first","affiliation":[{"name":"Attoquant Diagnostics, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus D","family":"S\u00e4emann","sequence":"first","affiliation":[{"name":"Department of Internal Medicine III, Clinical Division of Nephrology, Medical University of Vienna, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"H\u00fclsmann","sequence":"first","affiliation":[{"name":"Department of Internal Medicine II, Clinical Division of Cardiology, Medical University of Vienna, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2018,3,1]]},"reference":[{"key":"2020022606032906700_B1","doi-asserted-by":"crossref","first-page":"e137","DOI":"10.1161\/CIR.0000000000000509","article-title":"2017 ACC\/AHA\/HFSA focused update of the 2013 ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Task Force on clinical practice guidelines and the Heart Failure Society of America","volume":"136","author":"Yancy","year":"2017","journal-title":"Circulation"},{"key":"2020022606032906700_B2","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","article-title":"2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC), developed with the special contribution of the Heart Failure Association (HFA) of the ESC","volume":"37","author":"Ponikowski","year":"2016","journal-title":"Eur Heart J"},{"key":"2020022606032906700_B3","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1161\/CIRCRESAHA.116.307708","article-title":"Role of the ACE2\/Angiotensin 1\u20137 Axis of the renin-angiotensin system in heart failure","volume":"118","author":"Patel","year":"2016","journal-title":"Circ Res"},{"key":"2020022606032906700_B4","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1007\/s00109-008-0336-0","article-title":"Update on tissue renin-angiotensin systems","volume":"86","author":"Bader","year":"2008","journal-title":"J Mol Med (Berl)"},{"key":"2020022606032906700_B5","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.pharmthera.2008.08.009","article-title":"AT2 receptors: functional relevance in cardiovascular disease","volume":"120","author":"Jones","year":"2008","journal-title":"Pharmacol Ther"},{"key":"2020022606032906700_B6","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/nrcardio.2014.59","article-title":"Angiotensin-converting enzyme 2 and angiotensin 1\u20137: novel therapeutic targets","volume":"11","author":"Jiang","year":"2014","journal-title":"Nat Rev Cardiol"},{"key":"2020022606032906700_B7","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.1161\/01.RES.87.5.e1","article-title":"A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1\u20139","volume":"87","author":"Donoghue","year":"2000","journal-title":"Circ Res"},{"key":"2020022606032906700_B8","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1161\/CIRCRESAHA.108.184911","article-title":"Angiotensin(1\u20137) blunts hypertensive cardiac remodeling by a direct effect on the heart","volume":"103","author":"Mercure","year":"2008","journal-title":"Circ Res"},{"key":"2020022606032906700_B9","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1161\/01.HYP.34.2.296","article-title":"Angiotensin-(1\u20137) is a modulator of the human renin-angiotensin system","volume":"34","author":"Roks","year":"1999","journal-title":"Hypertension"},{"key":"2020022606032906700_B10","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1093\/cvr\/cvm021","article-title":"Chronic angiotensin IV treatment reverses endothelial dysfunction in ApoE-deficient mice","volume":"77","author":"Vinh","year":"2008","journal-title":"Cardiovasc Res"},{"key":"2020022606032906700_B11","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1093\/eurheartj\/ehs262","article-title":"Neutral endopeptidase inhibition and the natriuretic peptide system: an evolving strategy in cardiovascular therapeutics","volume":"34","author":"Mangiafico","year":"2013","journal-title":"Eur Heart J"},{"key":"2020022606032906700_B12","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.ejphar.2008.02.090","article-title":"Angiotensin-(1\u20137): pharmacological properties and pharmacotherapeutic perspectives","volume":"585","author":"Iusuf","year":"2008","journal-title":"Eur J Pharmacol"},{"key":"2020022606032906700_B13","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1093\/ndt\/gfw071","article-title":"Molecular regulation of the renin-angiotensin system in haemodialysis patients","volume":"31","author":"Kovarik","year":"2016","journal-title":"Nephrol Dial Transplant"},{"key":"2020022606032906700_B14","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1016\/j.jacc.2016.10.017","article-title":"Renin-angiotensin system fingerprints of heart failure with reduced ejection fraction","volume":"68","author":"Pavo","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"2020022606032906700_B15","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/j.jacc.2016.11.064","article-title":"Roles of angiotensin peptides and recombinant human ACE2 in heart failure","volume":"69","author":"Basu","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"2020022606032906700_B16","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1253\/circj.71.915","article-title":"Comparison of active renin concentration and plasma renin activity as a prognostic predictor in patients with heart failure","volume":"71","author":"Tsutamoto","year":"2007","journal-title":"Circ J"},{"key":"2020022606032906700_B17","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N Engl J Med"},{"key":"2020022606032906700_B18","article-title":"2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC","author":"Ponikowski","year":"2016","journal-title":"Eur J Heart Fail"},{"key":"2020022606032906700_B19","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.1161\/hy0102.102293","article-title":"Angiotensin II suppression in humans by the orally active renin inhibitor Aliskiren (SPP100): comparison with enalapril","volume":"39","author":"Nussberger","year":"2002","journal-title":"Hypertension"},{"key":"2020022606032906700_B20","first-page":"I46","article-title":"An inactive renin in human plasma","volume":"40","author":"Leckie","year":"1977","journal-title":"Circ Res"},{"key":"2020022606032906700_B21","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/0002-9343(91)90501-N","article-title":"Low angiotensinogen levels are related to the severity and liver dysfunction of congestive heart failure: implications for renin measurements","volume":"90","author":"Arnal","year":"1991","journal-title":"Am J Med"},{"key":"2020022606032906700_B22","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1159\/000181813","article-title":"Immunoradiometric assay of active renin versus determination of plasma renin activity in the clinical investigation of hypertension, congestive heart failure, and liver cirrhosis","volume":"34","author":"Plouin","year":"1990","journal-title":"Horm Res"},{"key":"2020022606032906700_B23","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1055\/s-2007-1004991","article-title":"Circadian variations of total renin, active renin, plasma renin activity and plasma aldosterone in clinically healthy young subjects","volume":"22","author":"Kawasaki","year":"1990","journal-title":"Horm Metab Res"},{"key":"2020022606032906700_B24","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1016\/j.cardfail.2010.06.417","article-title":"Elevated plasma renin activity predicts adverse outcome in chronic heart failure, independently of pharmacologic therapy: data from the Valsartan Heart Failure Trial (Val-HeFT)","volume":"16","author":"Masson","year":"2010","journal-title":"J Card Fail"},{"key":"2020022606032906700_B25","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.amjcard.2011.03.034","article-title":"Prognostic value of plasma renin activity in heart failure","volume":"108","author":"Vergaro","year":"2011","journal-title":"Am J Cardiol"},{"key":"2020022606032906700_B26","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1002\/cphy.c130040","article-title":"Classical renin-angiotensin system in kidney physiology","volume":"4","author":"Sparks","year":"2014","journal-title":"Compr Physiol"},{"key":"2020022606032906700_B27","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1016\/0002-8703(82)90045-X","article-title":"Determinants of acute and long-term response to converting enzyme inhibitors in congestive heart failure","volume":"104","author":"Levine","year":"1982","journal-title":"Am Heart J"},{"key":"2020022606032906700_B28","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.ehj.2003.10.030","article-title":"The comparative prognostic value of plasma neurohormones at baseline in patients with heart failure enrolled in Val-HeFT","volume":"25","author":"Latini","year":"2004","journal-title":"Eur Heart J"},{"key":"2020022606032906700_B29","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1046\/j.1365-2796.2001.00786.x","article-title":"Marked suppression of renin levels by beta-receptor blocker in patients treated with standard heart failure therapy: a potential mechanism of benefit from beta-blockade","volume":"249","author":"Holmer","year":"2001","journal-title":"J Intern Med"},{"key":"2020022606032906700_B30","first-page":"VI40","article-title":"Plasma norepinephrine, plasma renin activity, and congestive heart failure. Relations to survival and the effects of therapy in V-HeFT II. The V-HeFT VA Cooperative Studies Group","volume":"87","author":"Francis","year":"1993","journal-title":"Circulation"},{"key":"2020022606032906700_B31","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1161\/CIRCHEARTFAILURE.107.740704","article-title":"Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure","volume":"1","author":"McMurray","year":"2008","journal-title":"Circ Heart Fail"},{"key":"2020022606032906700_B32","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1001\/jama.2013.1954","article-title":"Effect of aliskiren on postdischarge mortality and heart failure readmissions among patients hospitalized for heart failure: the ASTRONAUT randomized trial","volume":"309","author":"Gheorghiade","year":"2013","journal-title":"JAMA"},{"key":"2020022606032906700_B33","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1136\/hrt.2006.107706","article-title":"Renin: friend or foe?","volume":"93","author":"Brown","year":"2007","journal-title":"Heart"},{"key":"2020022606032906700_B34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.amjhyper.2003.08.015","article-title":"Plasma renin activity levels in hypertensive persons: their wide range and lack of suppression in diabetic and in most elderly patients","volume":"17","author":"Alderman","year":"2004","journal-title":"Am J Hypertens"},{"key":"2020022606032906700_B35","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1111\/j.1365-2265.2007.02898.x","article-title":"Diagnosis and treatment of low-renin hypertension","volume":"67","author":"Mulatero","year":"2007","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2020022606032906700_B36","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1056\/NEJM197503272921311","article-title":"Editorial: Angiotensin blockade: new pharmacologic tools for understanding and treating hypertension","volume":"292","author":"Laragh","year":"1975","journal-title":"N Engl J Med"},{"key":"2020022606032906700_B37","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1161\/01.CIR.96.1.220","article-title":"Prorenin, renin, angiotensinogen, and angiotensin-converting enzyme in normal and failing human hearts. Evidence for renin binding","volume":"96","author":"Danser","year":"1997","journal-title":"Circulation"},{"key":"2020022606032906700_B38","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1161\/01.HYP.30.2.259","article-title":"Effect of bilateral nephrectomy on active renin, angiotensinogen, and renin glycoforms in plasma and myocardium","volume":"30","author":"Katz","year":"1997","journal-title":"Hypertension"}],"container-title":["Clinical Chemistry"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/clinchem\/article-pdf\/64\/3\/597\/32642370\/clinchem0597.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/clinchem\/article-pdf\/64\/3\/597\/32642370\/clinchem0597.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,26]],"date-time":"2020-02-26T11:10:03Z","timestamp":1582715403000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/clinchem\/article\/64\/3\/597\/5608842"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,1]]},"references-count":38,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2018,3,1]]},"published-print":{"date-parts":[[2018,3,1]]}},"URL":"https:\/\/doi.org\/10.1373\/clinchem.2017.278705","relation":{},"ISSN":["0009-9147","1530-8561"],"issn-type":[{"value":"0009-9147","type":"print"},{"value":"1530-8561","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2018,3,1]]},"published":{"date-parts":[[2018,3,1]]}}}